International Niemann–Pick Disease Alliance

Updates

  1. Sibling Spotlight: Sara

    As part of this year’s Niemann-Pick Disease Awareness Month, we are putting the spotlight on siblings as we feel they are often a huge support to both their brother or sister, as well as the broader family. They are also some...

    Read story
  2. Sibling Spotlight: Iker

    As part of this year’s Niemann-Pick Disease Awareness Month, we are putting the spotlight on siblings as we feel they are often a huge support to both their brother or sister, as well as the broader family. They are also some...

    Read story
  3. Sibling Spotlight: Guillermo

    As part of this year’s Niemann-Pick Disease Awareness Month, we are putting the spotlight on siblings as we feel they are often a huge support to both their brother or sister, as well as the broader family. They are also some...

    Read story
  4. Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

    Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) At closing combined Company will have approximately $13.7 million cash on hand to fund operations into 2H...

    Read story
  5. Advancing Rare Disease Research: Zevra’s Acquisition of Acer Therapeutics

    Read story
  6. Shining a Spotlight on Superstar Siblings: The Unsung Heroes of NPD Awareness Month

    Celebrating Strength and Support during NPD Awareness Month… …let’s shine a bright light on the unsung heroes of our Niemann-Pick Disease (NPD) community this October, during Niemann-Pick Disease Awareness Month. We’re thrilled to introduce our “Sibling Spotlight” campaign, dedicated...

    Read story
  7. Community Statement from Kisbee Therapeutics [30th August 2023]

    Read story
  8. Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

    – Data published in official journal of Molecular Genetics and Metabolism Reports: Evidence of a change in cholesterol homeostasis in peripheral organs and the brain after the initial infusion Trappsol® Cyclo™ was detected in the CSF Completers had an 88.9% improvement...

    Read story
  9. IntraBio Announces Positive Pivotal Trial Results of IB1001 for the Treatment of Niemann-Pick Disease Type C

    – Phase 3 trial met the primary endpoint and key secondary endpoints showing high statistical significance – IB1001 showed a clinically meaningful improvement in symptoms, functioning, quality of life, and cognition in both pediatric and adult patients with NPC...

    Read story
  10. Cyclo Therapeutics – Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients

     

    Read story

Join the Registry

Calling all patients and carers! We've created a global registry of all NPD patients - if you're not enrolled yet, join us now...

The Impact of NPC

The global community tell their stories...